Hypothesizing that the humoral arm of anti-tumor immunity could offer therapeutic opportunities with the potential to complement current CD8+ T-cell focussed immunotherapies, Ruffin et al. focused their analyses on B- and CD4+ Tconv cells [97]. The gene discussed is CD8A; the disease is neoplasm.